Current News

Contact | Print version | PDF version | Send article | RSS-Feed

DIREVO to collaborate with MedImmune on therapeutic protease for the treatment of CNS diseases

25 Jan 2008 - DIREVO Biotech AG announced the signing of a research and license agreement with MedImmune, the global biologics unit of AstraZeneca plc, to develop a therapeutic protease for the treatment of CNS diseases.
 
Under the terms of the agreement, Direvo will be applying its proprietary protein-engineering capabilities to create specifically engineered proteases. MedImmune will then be responsible for the development and marketing of the protease product that may arise under the agreement. Direvo will receive undisclosed upfront and milestone payments, as well as research funding plus royalties on potential sales of the therapeutic protease should it reach the market.